{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:27:54Z","timestamp":1782941274286,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejso.2025.109628","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T03:33:13Z","timestamp":1737430393000},"page":"109628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cytoreductive surgery in diffuse pleural mesothelioma. What have we learnt from MARS2, EORTC-L1205 and other recent studies?"],"prefix":"10.1016","volume":"51","author":[{"given":"Lo\u00efc","family":"Lang-Lazdunski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2025.109628_bib1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American society of clinical oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.109628_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejso.2025.109628_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2025.109628_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2025.109628_bib5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief report: real-world toxicity and survival of combination immunotherapy in pleural mesothelioma-RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejso.2025.109628_bib6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2025.109628_bib7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/JTO.0b013e31824ab6c5","article-title":"Pleurectomy\/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma","volume":"7","author":"Lang-Lazdunski","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejso.2025.109628_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"MARS2: extended pleurectomy decortication and chemotherapy for pleural mesothelioma","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ejso.2025.109628_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02114-2023","article-title":"A randomized phase II study of extended pleurectomy\/decortication (ePD) preceded or followed by chemotherapy in patients with early stage malignant pleural mesothelioma: EORTC 1205","author":"Raskin","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejso.2025.109628_bib10","unstructured":"Waller D. https:\/\/www.ctsnet.org\/article\/objective-discrepancies-mars-2-trial-interview-david-waller."},{"key":"10.1016\/j.ejso.2025.109628_bib11","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/ejcts\/ezv403","article-title":"The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy decortication","volume":"49","author":"Sharkey","year":"2016","journal-title":"Eur J Cardio Thorac Surg"},{"key":"10.1016\/j.ejso.2025.109628_bib12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jtcvs.2014.10.041","article-title":"Pleurectomy\/decortication, hyperthermic pleural lavage, prophylactic radiotherapy and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience","volume":"149","author":"Lang-Lazdunski","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"10","key":"10.1016\/j.ejso.2025.109628_bib13","doi-asserted-by":"crossref","first-page":"S757","DOI":"10.1016\/j.jtho.2019.08.1623","article-title":"Multimodality therapy using total pleurectomy in malignant pleural mesothelioma: long-term outcomes in 150 consecutive cases","volume":"14","author":"Lang-Lazdunski","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejso.2025.109628_bib14","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.21037\/jtd-21-691","article-title":"Long-term outcomes after lung-sparing surgery for epithelial mesothelioma","volume":"13","author":"Breda","year":"2021","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ejso.2025.109628_bib15","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.21037\/tlcr-22-199","article-title":"Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach","volume":"11","author":"Klotz","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejso.2025.109628_bib16","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.athoracsur.2016.08.071","article-title":"Extended pleurectomy\/decortication-based treatment for advanced stage, epithelial mesothelioma yielding a median survival of nearly three years","volume":"103","author":"Friedberg","year":"2017","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"10.1016\/j.ejso.2025.109628_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/ejcts\/ezae431","article-title":"Surgery for pleural mesothelioma in multimodality setting: comparison between surgical techniques in a high-volume centre","volume":"66","author":"Faccioli","year":"2024","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.ejso.2025.109628_bib18","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/SLA.0000000000004306","article-title":"Pleurectomy decortication in the treatment of malignant pleural mesothelioma: encouraging results and novel prognostic implications based on experience in 355 consecutive patients","volume":"275","author":"Lapidot","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2025.109628_bib19","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.3390\/jcm11226839","article-title":"The effects of preserving the diaphragm on early and late outcome of lung-sparing radical surgery for malignant pleural mesothelioma","volume":"11","author":"Lee","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejso.2025.109628_bib20","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/JTO.0b013e31824de2dc","article-title":"Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma","volume":"7","author":"B\u00f6l\u00fckbas","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejso.2025.109628_bib21","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jtho.2019.04.029","article-title":"A proposed system toward standardizing surgical-based treatments for malignant pleural mesothelioma, from the joint national cancer institute\u2013international association for the study of lung cancer\u2013mesothelioma applied research foundation taskforce","volume":"14","author":"Friedberg","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejso.2025.109628_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113457","article-title":"Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma","volume":"196","author":"De Miguel-Perez","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2025.109628_bib23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.path.2023.11.013","article-title":"Applications of artificial intelligence in lung pathology","volume":"17","author":"Hartman","year":"2024","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.ejso.2025.109628_bib24","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.jtho.2023.08.005","article-title":"The International Association for the Study of Lung Cancer mesothelioma staging project: updating modeling of prognostic factors in pleural mesothelioma","volume":"12","author":"Wolf","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejso.2025.109628_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007585","article-title":"PD-1 expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma","author":"Homicsko","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejso.2025.109628_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejso.2025.109628_bib27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/his.14127","article-title":"Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade","volume":"77","author":"Zhang","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.ejso.2025.109628_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/PAS.0000000000001416","article-title":"Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in biopsy-heavy setting: an external validation study of 563 cases","volume":"44","author":"Zhang","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejso.2025.109628_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-00831-4","article-title":"Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort","volume":"11","author":"Cedres","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejso.2025.109628_bib30","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jtcvs.2019.08.027","article-title":"Survival results in biphasic malignant pleural mesothelioma patients: a multicentric analysis","volume":"159","author":"Lococo","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejso.2025.109628_bib31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1078-0432.CCR-22-2566","article-title":"A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 blockade for patients with malignant pleural mesothelioma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2025.109628_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910861","article-title":"Immunotherapy for the treatment of pleural mesothelioma: current and emerging therapeutic strategies","volume":"25","author":"Chiec","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejso.2025.109628_bib33","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2025.109628_bib34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2025.109628_bib35","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1470-2045(20)30606-9","article-title":"Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre , phase 2 trial","volume":"22","author":"Cho","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2025.109628_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/jso.27243","article-title":"Malignant pleural mesothelioma characteristics and outcomes: a SEER-Medicare analysis","volume":"128","author":"Taioli","year":"2023","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejso.2025.109628_bib37","first-page":"298","article-title":"Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy","volume":"40","author":"Sugarbaker","year":"2011","journal-title":"Eur J Cardio Thorac Surg"},{"key":"10.1016\/j.ejso.2025.109628_bib38","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jtho.2022.03.014","article-title":"Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations","volume":"17","author":"Carbone","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejso.2025.109628_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/PO.20.00260","article-title":"Durable response to vismodegib in PTCH1 F1147 fs mutant relapsed malignant pleural mesothelioma: implications for mesothelioma drug treatment","volume":"5","author":"Popat","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejso.2025.109628_bib40","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"Lopez-Rios","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejso.2025.109628_bib41","first-page":"77","volume":"15","author":"Gould","year":"2013","journal-title":"Virtual Mentor"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325000563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325000563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T05:44:10Z","timestamp":1755495850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325000563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0748798325000563"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.109628","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytoreductive surgery in diffuse pleural mesothelioma. What have we learnt from MARS2, EORTC-L1205 and other recent studies?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.109628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109628"}}